| Literature DB >> 30584310 |
Cong Chen1,2, Shumin Huang3, Aihua Huang1,2, Yunlu Jia1,2, Ji Wang1,2, Misha Mao1,2, Jichun Zhou1,2, Linbo Wang1,2.
Abstract
BACKGROUND: Despite the considerable experience gained thus far using endoscopic technologies, the role of total endoscopic thyroidectomy (ET) for papillary thyroid cancer (PTC) remains controversial. We conducted a systematic review and meta-analysis to investigate the safety and effectiveness of total ET compared with conventional open thyroidectomy (OT) in PTC.Entities:
Keywords: conventional open thyroidectomy; endoscopic thyroidectomy; meta-analysis; papillary thyroid carcinoma
Year: 2018 PMID: 30584310 PMCID: PMC6287425 DOI: 10.2147/TCRM.S183612
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Figure 1Flow diagram for study selection.
Abbreviation: FTC, follicular thyroid cancer.
General characteristics of studies included in the meta-analysis
| Study (first author, year) | Region | Study type | No of patients
| Age (years), mean ± SD ET OT
| Gender, M/F
| Extent of thyroidectomy, TT/LTT
| Surgical approach | Matching | Quality score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ET | OT | ET | OT | ET | OT | ET | OT | ||||||
|
| |||||||||||||
| Chung 2007 | Korea | RS | 103 | 198 | 38.2±8.2 | 47.2±10.2 | 1/102 | 25/173 | 88/15 | 172/26 | BABA | 4, 9 | 6 |
| Hong 2011 | Korea | RS | 57 | 60 | 39.60±7.88 | 41.77±9.61 | 6/51 | 11/49 | 0/57 | 0/60 | BABA/UABA | 1, 2, 4, 7, 9 | 7 |
| Kim 2011 | Korea | RS | 95 | 138 | 39.9±9.1 | 51.8±8.9 | 2/93 | 34/104 | 95/0 | 138/0 | BABA | 9 | 6 |
| Tae 2011 | Korea | RS | 31 | 36 | 36.2±9.9 | 44.6±11.8 | 1/30 | 11/25 | 3/28 | 0/36 | UABA/TAA | 4–9 | 7 |
| Lee 2012 | Korea | RS | 37 | 41 | 42.3±7.6 | 49.0±10.8 | 0/37 | 3/38 | 0/37 | 0/41 | TAA | 2, 4, 5, 7–9 | 7 |
| Tan 2015 | China | RS | 34 | 30 | 30 (16–44) | 43 (25–76) | 2/32 | 4/26 | 0/34 | 0/30 | BBA | 2, 4, 9 | 7 |
| Huang 2016 | China | RS | 75 | 123 | 37.8±10.6 | 39.2±11.3 | 16/59 | 31/92 | 75/0 | 123/0 | TAA | 1–5, 7–9 | 7 |
| Kim 2016 | Korea | RS | 173 | 830 | 38.90 (17–57) | 49.53 (17–84) | 13/160 | 96/734 | 56/117 | 684/146 | BABA | 2 | 5 |
| Lee 2016 | Korea | RS | 75 | 233 | 42.2±8.6 | 52.1±9.3 | 3/72 | 15/218 | 0/75 | 0/233 | BABA/UABA | 2, 4, 5, 7, 9 | 6 |
| Park 2016 | Korea | RS | 50 | 102 | 38.0±9.4 | 50.8±11.5 | 4/46 | 14/88 | 50/0 | 102/0 | UABA | 2, 4–7, 9 | 5 |
| Xiang 2016 | China | RS | 49 | 47 | 34.2±7.0 | 46.9±13.3 | 0/49 | 6/41 | 49/0 | 47/0 | BBA | 7, 9 | 6 |
| Ren 2017 | China | RS | 20 | 35 | 36.05±7.536 | 36.06±5.646 | 0/20 | 0/35 | 0/20 | 0/35 | BBA | 1–3, 9 | 6 |
Notes:
Features matching ET and OT: 1 = age; 2 = gender; 3 = body mass index; 4 = tumor size; 5 = multiplicity; 6 = bilaterality; 7 = extrathyroidal extension; 8 = tumor stage; 9 = extent of thyroidectomy.
Median (range).
Abbreviations: BABA, bilateral axillobreast approach; BBA, bilateral breast approach; ET, endoscopic thyroidectomy; F, female; LTT, less than total thyroidectomy; M, male; OT, open thyroidectomy; RS, retrospective study; TAA, transaxillary approach; TT, total thyroidectomy; UABA, unilateral axillobreast approach.
Pathological characteristics of studies included in the meta-analysis
| Study (first author, year) | Tumor size (mm)
| Multiplicity (n/N)
| Bilaterality (n/N)
| Extrathyroidal extension (n/N)
| Positive LNs (n/N)
| No of metastatic LNs
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ET | OT | ET | OT | ET | OT | ET | OT | ET | OT | ET | OT | |
|
| ||||||||||||
| Chung 2007 | <10 | <10 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Hong 2011 | 7.25±2.30 | 7.10±2.65 | NR | NR | NR | NR | 10/57 | 19/60 | 21/57 | 26/60 | 1.30±1.83 | 1.43±1.87 |
| Kim 2011 | 6.0±2.0 | 7.0±2.0 | NR | NR | NR | NR | NR | NR | NR | NR | 0.9±2.0 | 0.5±0.9 |
| Tae 2011 | 7.6±4.9 | 6.4±2.3 | 2/31 | 2/36 | 0/31 | 0/36 | 2/31 | 1/36 | 4/16 | 2/12 | NR | NR |
| Lee 2012 | 5.0±2.31 | 4.1±2.64 | 3/37 | 5/41 | NR | NR | 1/37 | 2/41 | 5/37 | 1/41 | NR | NR |
| Tan 2015 | 7.0±3.0 | 8.0±4.0 | NR | NR | NR | NR | NR | NR | 8/34 | 4/30 | 0.8±2.0 | 0.2±0.7 |
| Huang 2016 | 4.8±1.9 | 4.9±2.3 | 5/75 | 9/123 | NR | NR | 2/75 | 4/123 | 9/75 | 11/123 | NR | NR |
| Kim 2016 | NR | NR | NR | NR | NR | NR | 4/173 | 128/830 | 34/173 | 312/830 | NR | NR |
| Lee 2016 | 5.8±3.5 | 6.2±3.7 | 12/75 | 30/233 | NR | NR | 21/75 | 93/233 | 12/75 | 35/233 | NR | NR |
| Park 2016 | 8.0±3.7 | 7.6±1.9 | 7/50 | 19/102 | 10/50 | 18/102 | 28/50 | 70/102 | NR | NR | 0.7±1.4 | 0.6±1.2 |
| Xiang 2016 | 7.7±4.2 | 12.4±7.9 | 26/49 | 37/47 | NR | NR | 3/49 | 8/47 | 20/49 | 40/47 | NR | NR |
| Ren 2017 | <10 | <10 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Overall | 6.4±3.2 | 6.7±3.7 | 55/317 | 102/582 | 10/81 | 18/138 | 71/547 | 325/1,472 | 113/516 | 431/1,376 | 0.9±1.8 | 0.7±1.3 |
Abbreviations: ET, endoscopic thyroidectomy; LN, lymph node; NR, not reported; OT, open thyroidectomy.
Outcomes of meta-analysis comparing ET vs OT
| Outcomes | No of studies | No of patients
| OR/WMD | 95% CI | |||
|---|---|---|---|---|---|---|---|
| ET | OT | ||||||
| Intraoperative outcomes | |||||||
| Operative time | 11 | 724 | 1,640 | 50.46 | 40.50, 60.42 | <0.00001 | 87 |
| No of retrieved LNs | 10 | 676 | 1,640 | −0.53 | −1.29, 0.22 | 0.17 | 80 |
| Blood loss | 4 | 179 | 290 | 4.37 | −2.62, 11.36 | 0.22 | 72 |
| Postoperative outcomes | |||||||
| Duration of drainage | 3 | 104 | 167 | 1.88 | 1.22, 2.54 | <0.00001 | 76 |
| Volume of drainage | 5 | 230 | 341 | 111.96 | 61.66, 162.26 | <0.0001 | 95 |
| Hospitalization period | 8 | 566 | 1,440 | 0.65 | 0.06, 1.24 | 0.03 | 90 |
| Transient RLN palsy | 11 | 762 | 1,832 | 2.64 | 1.36, 5.11 | 0.004 | 48 |
| Permanent RLN palsy | 9 | 653 | 1,679 | 2.04 | 0.80, 5.23 | 0.14 | 0 |
| Transient hypocalcemia | 8 | 555 | 1,416 | 0.93 | 0.46, 1.87 | 0.84 | 81 |
| Permanent hypocalcemia | 7 | 521 | 1,386 | 0.82 | 0.39, 1.69 | 0.58 | 0 |
| Hematoma or bleeding | 10 | 674 | 1,538 | 1.76 | 0.81, 3.81 | 0.15 | 0 |
| Seroma | 4 | 258 | 357 | 1.33 | 0.53, 3.34 | 0.54 | 0 |
| Oncological outcomes | |||||||
| sTg <1.0 ng/mL | 2 | 29 | 343 | 0.33 | 0.13, 0.81 | 0.02 | 0 |
| Tumor recurrences | 6 | 398 | 1,170 | 0.54 | 0.22, 1.32 | 0.18 | 0 |
Abbreviations: ET, endoscopic thyroidectomy; LN, lymph node; OT, open thyroidectomy; RLN, recurrent laryngeal nerve; sTg, stimulated thyroglobulin; WMD, weighted mean difference.
Figure 2Forest plot and meta-analysis of (A) operative time; (B) number of retrieved lymph nodes; (C) blood loss.
Abbreviations: ET, endoscopic thyroidectomy; OT, open thyroidectomy.
Figure 3Forest plot and meta-analysis of (A) duration of drainage; (B) volume of drainage; (C) hospitalization period.
Abbreviations: ET, endoscopic thyroidectomy; OT, open thyroidectomy.
Figure 4Forest plot and meta-analysis of (A) transient RLN palsy; (B) permanent RLN palsy; (C) transient hypocalcemia; (D) permanent hypocalcemia; (E) hematoma or bleeding; (F) seroma.
Abbreviations: ET, endoscopic thyroidectomy; M–H, Mantel–Haenszel; OT, open thyroidectomy; RLN, recurrent laryngeal nerve.
Figure 5Forest plot and meta-analysis of (A) number of sTg <1 ng/mL; (B) number of tumor recurrences.
Abbreviations: ET, endoscopic thyroidectomy; M–H, Mantel–Haenszel; OT, open thyroidectomy; sTg, stimulated thyroglobulin.
Meta-analysis of the subgroups according to the extent of thyroidectomy
| Outcomes | No of studies | No of patients
| OR/WMD | 95% CI | |||
|---|---|---|---|---|---|---|---|
| ET | OT | ||||||
|
| |||||||
| TT | |||||||
| Operative time | 4 | 269 | 410 | 47.40 | 34.18, 60.61 | <0.00001 | 84 |
| No of retrieved LNs | 4 | 269 | 410 | −0.10 | −0.50, 0.30 | 0.63 | 0 |
| Blood loss | 2 | 125 | 225 | 2.35 | −7.27, 11.97 | 0.63 | 79 |
| Volume of drainage | 2 | 145 | 240 | 100.31 | −33.67, 234.29 | 0.14 | 94 |
| Hospitalization period | 2 | 145 | 240 | 0.33 | 0.10, 0.56 | 0.005 | 0 |
| Transient RLN palsy | 4 | 269 | 410 | 1.58 | 0.66, 3.79 | 0.31 | 0 |
| Permanent RLN palsy | 3 | 194 | 287 | 1.89 | 0.49, 7.33 | 0.36 | 20 |
| Transient hypocalcemia | 3 | 194 | 287 | 1.48 | 0.68, 3.20 | 0.32 | 70 |
| Permanent hypocalcemia | 3 | 194 | 287 | 1.35 | 0.46, 3.99 | 0.58 | 0 |
| Hematoma or bleeding | 3 | 219 | 308 | 2.93 | 0.61, 14.02 | 0.18 | 0 |
| Seroma | 2 | 170 | 261 | 0.67 | 0.10, 4.55 | 0.68 | 0 |
| LTT | |||||||
| Operative time | 4 | 148 | 166 | 45.96 | 29.33, 62.59 | <0.00001 | 90 |
| No of retrieved LNs | 4 | 203 | 364 | −0.89 | −2.48, 0.70 | 0.27 | 90 |
| Blood loss | 2 | 54 | 65 | 6.52 | −0.72, 13.76 | 0.08 | 46 |
| Duration of drainage | 2 | 54 | 65 | 2.20 | 1.82, 2.59 | <0.00001 | 0 |
| Volume of drainage | 2 | 54 | 65 | 114.99 | 99.74, 130.24 | <0.00001 | 0 |
| Hospitalization period | 3 | 114 | 136 | 0.81 | −0.19, 1.82 | 0.11 | 95 |
| Transient RLN palsy | 4 | 186 | 358 | 2.83 | 1.26, 6.36 | 0.01 | 44 |
| Permanent RLN palsy | 3 | 152 | 328 | 5.29 | 0.54, 52.22 | 0.15 | 0 |
| Transient hypocalcemia | 2 | 54 | 65 | 0.31 | 0.07, 1.36 | 0.12 | 0 |
| Hematoma or bleeding | 4 | 148 | 166 | 2.20 | 0.62, 7.84 | 0.22 | 0 |
Abbreviations: ET, endoscopic thyroidectomy; LN, lymph node; LTT, less than total thyroidectomy; OT, open thyroidectomy; RLN, recurrent laryngeal nerve; TT, total thyroidectomy; WMD, weighted mean difference.
Pooled surgical outcomes between ET and OT groups from all eligible studies
| Outcomes | ET | OT | References |
|---|---|---|---|
|
| |||
| Intraoperative outcomes | |||
| Operative time (minutes) | 142.0±45.9 | 92.3±36.6 | 7, 27–31, 34–36 |
| No of retrieved LNs | 4.3±4.1 | 4.7±4.0 | 7, 27–31, 33–35 |
| Blood loss (mL) | 19.6±24.5 | 14.5±9.8 | 7, 31, 34, 36 |
| Postoperative outcomes | |||
| Duration of drainage (days) | 5.9±1.9 | 4.6±2.0 | 31, 34, 36 |
| Volume of drainage (mL) | 202.3±142.0 | 112.7±56.9 | 28, 29, 31, 34, 36 |
| Hospitalization period (days) | 5.3±2.5 | 4.8±2.9 | 27–30, 34, 36 |
| Transient RLN palsy, n (%) | 64 (8.3) | 60 (3.3) | 7, 26–29, 31–36 |
| Permanent RLN palsy, n (%) | 7 (1.1) | 8 (0.5) | 26–29, 32–36 |
| Transient hypocalcemia, n (%) | 116 (20.9) | 366 (25.8) | 26, 28, 29, 31, 32, 34–36 |
| Permanent hypocalcemia, n (%) | 10 (1.9) | 31 (2.2) | 26, 28, 29, 32, 34–36 |
| Hematoma or bleeding, n (%) | 13 (1.9) | 17 (1.1) | 7, 26–32, 35, 36 |
| Seroma, n (%) | 10 (3.9) | 9 (2.5) | 7, 27–29 |
| Oncological outcomes | |||
| sTg <1.0 ng/mL, n (%) | 9 (31.0) | 176 (51.3) | 26, 32 |
| Tumor recurrences, n (%) | 6 (1.5) | 31 (2.6) | 26, 29–32, 36 |
Abbreviations: ET, endoscopic thyroidectomy; LN, lymph node; OT, open thyroidectomy; RLN, recurrent laryngeal nerve; sTg, stimulated thyroglobulin.
Figure 6Funnel plot of transient recurrent laryngeal nerve palsy in all included studies.